Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
December 19, 2011
Cytori (CYTX), IDE Filing for Chronic Myocardial Ischemia
December 16, 2011
RegMed Daily, Mid-Day, 12/16/11, stocks moving higher, trading subdued
December 14, 2011
RegMed Daily, Mid-Day, 12/14/11, an over sell-off is happening, as the EU sneezes
December 9, 2011
RegMed Daily, Mid-Day, 12/9/11, finally some sector movement
December 5, 2011
RegMed Daily, Mid-Day, 12/5/11, the rally is getting beyond the moving averages
November 30, 2011
RegMed Daily, Mid-Day, 11/30/11, EU, jobs and econ data continue to dominate markets
November 30, 2011
Cytori's (CYTX) Celution(R) One receives EU CE Mark Approval
November 29, 2011
RegMed Daily, Mid-Day, 11/29/11, more alphabet agencies in EU busily finalize approving Greek aid
November 28, 2011
RegMed Daily, Mid-Day, 11/28/11, stocks rally with optimism for the EU
November 19, 2011
Earnings Report Card Additions, Q3/11, Regenerative Medicine Universe …
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cytori (CYTX) – Started the year seeking "strategic alternatives" with a share priced at $0.29, seeing a couple of highs of $0.47 with a 2/1 value of $0.40 which has been dropping and currently (2/16) at $0.32. A sory of missed oppurtunity thrown at the feet of its CEO ... incremental development news are minimal ... it's all about whether the FDA requests ... MORE data and trial.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.